PD-L1 specific monoclonal antibodies for disease treatment and diagnosis
US10077308B2 · kind B2 · utility
4Cited by
0References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 12, 2017 |
| Grant date | Sep 18, 2018 |
| Priority date | — |
| Expiry date | Jun 12, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-PD-L1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.